Glofitamab
MCE 国际站:Glofitamab
CAS:2229047-91-8
品牌:MedChemExpress (MCE)
存储条件:Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性:Glofitamab (RO7082859) 是一种结合 T 细胞的双特异性抗体,具有新型 2:1 结构,对 B 细胞上的 CD20 具有二价性,对 T 细胞上的 CD3 具有单价性。 Glofitamab 在与恶性细胞上的 CD20 结合后导致 T 细胞活化、增殖和肿瘤细胞杀伤。 Glofitamab 可诱导复发或难治性 B 细胞淋巴瘤的持久完全缓解[1][2]。
热销产品:Galunisertib | Calcipotriol | Daratumumab | SH-42 | Gefitinib | Pazopanib | Banoxantrone (dihydrochloride) | Curcumin | Zanubrutinib | Ipilimumab
作用靶点:CD20
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
参考文献:
[1]. Hutchings M, et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021;39(18):1959-1970. [2]. Bröske AE, et al. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma. Blood Adv. 2022;6(3):1025-1037.